Dill: I think the move we're seeing in the stock is indicative of just how hungry we are for great news in this space. If you were looking to add to a position or start a position in biojen, i would say, there's no reason to go both feet in, but i wouldn't be adverse," he says. "If it's real, then biogen has much, much further to go in terms of the stock price"
Volkswagen spun off its investment in Porsche for the first big name IPO of 2022. It only took until late September!
(0:18) Dylan Lewis and Tim Beyers discuss: - Why Porsche is going public while other companies are holding off. - Down rounds in the private markets. - Promising results for Biogen’s Alzheimer’s treatment.
Mortgage rates have doubled in the past year. (13:33) Deidre Woollard and Matt Argersinger look at the ripple effects and which companies could benefit from the shift.
Companies mentioned: P911, VWAPY, RACE, BIIB, HD, Z, AOS, WSO, OPEN, LOW
Host: Dylan Lewis Guests: Tim Beyers, Matt Argersinger, Deidre Woolard Producer: Ricky Mulvey Engineers: Rick Engdahl, Tim Sparks
Learn more about your ad choices. Visit megaphone.fm/adchoices